LabCorp Introduces Xcellerate COVID-19 Clinical Study Solution

By Contract Pharma Staff | 06.29.20

Offers integrated data collection, actionable views of critical study data, COVID-19 targeted risk management and recovery assessment.

LabCorp announced that Covance, its drug development business, has deployed the Xcellerate COVID-19 solution, a comprehensive approach to reinitiate ongoing research and start up new studies, with a focus on patient safety and study delivery. Designed in conjunction with Covance’s COVID-19 Operational Recovery Team, the Xcellerate COVID-19 solution offers integrated data collection, actionable views of critical study data, COVID-19 targeted risk management and recovery assessment.

Global clinical research has been disrupted by the COVID-19 pandemic with studies being halted or paused and enrollment being delayed. Many clinical research sites around the world have restricted all but essential visits except for patient safety, with study monitoring conducted remotely where possible. As healthcare conditions improve globally, research sites are positioned to resume studies.

The Xcellerate COVID-19 solution combines different components of the Xcellerate informatics suite to create a tailored data collection capability, risk assessment tools, centralized monitoring and advanced metrics reporting. Its visualization dashboards provide actionable views of critical study data so that operational teams can make effective decisions, increase efficiency and reduce risk.